Junshi Biosciences to Study JS016, a Novel Coronavirus Neutralizing Antibody Product Candidate

In its second quarter earnings release, Junshi Biosciences announced that its product candidate JS016 was approved to conduct a Phase 1 clinical trial in China. The trial is a randomized, double-blind, placebo-controlled study to evaluate the tolerability and safety of single-dose intravenous infusion of JS106 in healthy subjects. According to Junshi, this study is the world’s first novel coronavirus neutralizing antibody clinical trial conducted in healthy subjects, and Junshi plans to enroll a total of 40 subjects. Junshi also noted additional ongoing and planned studies in patients with novel coronavirus pneumonia, as well as follow-up studies to evaluate the preventative effect of JS016 on novel coronavirus infection.